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Abstract
Patient-Powered Research Networks (PPRNs) are US-based registry infrastructures co-created by advocacy groups, patient 
research partners, academic investigators, and other healthcare stakeholders. Patient-Powered Research Networks collect 
information directly from patients to conduct and disseminate the results of patient-centered/powered research that helps 
patients make more informed decisions about their healthcare. Patient-Powered Research Networks gather and utilize real-
world data and patient-reported outcomes to conduct comparative effectiveness, safety, and other research, and leverage the 
Internet to accomplish this effectively and efficiently. Four PPRNs focused on autoimmune and immune-mediated condi-
tions formed the Autoimmune Research Collaborative: ArthritisPower (rheumatoid arthritis, spondyloarthritis, and other 
rheumatic and musculoskeletal diseases), IBD Partners (inflammatory bowel disease), iConquerMS (multiple sclerosis), and 
the Vasculitis PPRN (vasculitis). The Autoimmune Research Collaborative aims to inform the healthcare decision making of 
patients, care partners, and other stakeholders, such as clinicians, regulators, and payers. Illustrated by practical applications 
from the Autoimmune Research Collaborative and its constituent PPRNs, this article discusses the shared capacities and 
challenges of the PPRN model, and the opportunities presented by collaborating across autoimmune conditions to design, 
conduct, and disseminate patient-centered outcomes research.
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1 Introduction
People living with autoimmune conditions frequently make 
critical decisions about treatments involving costly and 
innovative medications, often with little data comparing the 
treatments’ effectiveness or safety to guide such decisions. 
Furthermore, existing clinical trial research in the field has 
primarily utilized data from images, laboratory tests, and 
clinical assessments under the control of providers [1]. Such 
partiality for provider-sourced data may under-appreciate 
or under-measure patient-reported outcomes (PROs) or 
other patient-generated data that patients themselves deem 
important [2–4]. Patient-reported outcomes constitute an 
assessment of symptoms or disease coming directly from 
the patient without interpretation by an intermediary [5]. 
Little longitudinal real-world evidence incorporating PROs 
exists to help inform patients with autoimmune diseases, 
and other stakeholders, about patients’ experiences while 
receiving immunomodulating therapies, including patterns 
in their disease activity and symptoms. Patient-centered out-
comes research is characterized by engagement of patients 
throughout the research process and inclusion of research 
questions and outcomes important to patients and care part-
ners, such as PROs and other measures related to quality of 
life, disease symptoms, and safety [6, 7]. Patient-centered 
outcomes research can be especially important to people 
living with immune-mediated conditions who make choices 
from an array of therapy options, and want to know about 
the experiences of similarly situated individuals receiving 
such therapies [8]. In principle, patient-centered outcomes 
research: encourages researchers to learn how treatments 
affect patients’ ability to manage symptoms and maintain 
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(Internet/Web) and/or smartphone-based portals that provide 
patients with the ability to propose research questions and 
access research opportunities directly, rather than relying on 
physician solicitation for participation. Each PPRN func-
tions as a registry or secured repository of patient-generated 
data and observational electronic health information.
In 2019, four PPRNs formed the Autoimmune Research 
Collaborative: ArthritisPower (rheumatoid arthritis, spon-
dyloarthritis, osteoarthritis, and other rheumatic and mus-
culoskeletal diseases), IBD Partners (inflammatory bowel 
disease), iConquerMS (multiple sclerosis), and the Vascu-
litis Patient-Powered Research Network (multiple forms of 
vasculitis). The four constituent PPRNs of the ARC have 
a shared history rooted in the development and launch of 
the National Patient-Centered Clinical Research Network 
(PCORnet) that began in December 2013 when PCORI’s 
Board of Governors approved phase I, 18-month funding 
for an initial group of 29 partner networks. These networks 
included health system-based Clinical Research Networks, 
patient-initiated PPRNs, and a Coordinating Center to lead 
development of the PCORnet Common Data Model, har-
monization of data and processes, and fielding of PCORnet 
data queries [12]. A second phase of infrastructure develop-
ment involving 13 Clinical Research Networks, 20 PPRNs, 
two Health Plan Research Networks, and the Coordinating 
Center operated from the fall of 2015 through 2018. While 
Clinical Research Networks “... are based on electronic 
health record (EHR) data and other electronic sources related 
to large patient populations within health care systems,” and 
Health Plan Research Networks are based on claims data 
from health plans, PPRNs mobilize communities of patients 
with a single medical condition or several related conditions 
who participate in research that generates new knowledge for 
patients similarly affected by the condition(s) [13]. Patient 
members of PPRNs contribute their self-reported and EHR 
data, and help to guide and govern the network’s research 
activities [11]. In 2016, four PPRNs chartered the PCORnet 
Autoimmune and Systemic Inflammatory Syndromes Col-
laborative Research Group to develop new research across 
common areas of interest within PCORnet and to advance 
network sustainability.
In its current pared-down form, PCORnet includes nine 
Clinical Research Networks, two Health Plan Research Net-
works, a Coordinating Center, but no PPRNs [14]. Although 
funding constraints have meant that PPRNs were no longer 
considered part of PCORnet beyond phase II, the four 
PPRNs leading the Autoimmune and Systemic Inflammatory 
Syndromes Collaborative Research Group formed the ARC 
(or “the Collaborative”) to build on momentum from their 
prior work. The ARC offers a mechanism for research col-
laborators to engage one or more PPRNs simultaneously for 
projects across autoimmune diseases. The Collaborative’s 
Key Points for Decision Makers 
Patient-Powered Research Networks conduct a range of 
direct-to-patient research activities comprising digi-
tal research recruitment and data collection methods, 
innovative informatics, including computable pheno-
types, and novel methods for data linkage, and systems 
that promote dissemination of relevant information to 
patients and other healthcare stakeholders.
Four Patient-Powered Research Networks focused on 
autoimmune and immune-mediated conditions formed 
the Autoimmune Research Collaborative with individual 
and collective capacity to respond to research questions 
using existing and new data and scalable infrastructure.
their quality of life, often using information collected 
directly from patients; engages patients throughout the 
research process by weighing in on study objectives, design, 
conduct, implementation, and dissemination; and speeds dis-
semination of research findings back to patients and other 
stakeholders to help them to use the most up-to-date infor-
mation in their healthcare decisions [6, 7, 9].
Patient-Powered Research Networks (PPRN) focusing on 
autoimmune conditions are well positioned for real-world 
patient-centered outcomes research that provides benefit to 
patients and other stakeholders. The PPRN model has fea-
tures that confer clear advantages for patient-centered out-
comes research, but are also accompanied by inherent chal-
lenges. Four US-based PPRNs formed a collaborative group 
for discussion, planning, action, and reflection, to build on 
the strength of the PPRN model and address its vulnerabili-
ties. This article describes the shared history, characteristics, 
capacity, and challenges of the PPRNs comprising the Auto-
immune Research Collaborative (ARC) and shares practical 
examples of, and opportunities for, implementing patient-
centered outcomes research.
2  History and Structure: The PPRNs 
Comprising the ARC 
Ensuring that patients, the end users of healthcare research 
results, are engaged in research is a foundational priority for 
the PPRNs that were initially established with infrastructure 
support from the Patient-Centered Outcomes Research Insti-
tute (PCORI) [10–12], a non-profit government-sponsored 
organization created by the 2010 Patient Protection and 
Affordable Care Act. Patient-Powered Research Networks 
grew out of existing patient organizations or communities 
in partnership with academic centers, and they use online 
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purpose is to individually and collectively cultivate inno-
vative patient-investigator partnerships in autoimmune 
patient-centered outcomes research that engage and evolve 
our shared PPRN infrastructure.
Each PPRN member of the ARC is a partnership of 
patients, care partners, researchers, and non-profit advocacy 
organizations that engage directly with patients, typically 
outside of clinical settings and often digitally or online: a 
“direct-to-patient” approach to research. Although ran-
domized controlled trials are the gold standard for health 
research, they are often restrictive because of the costs of 
enrolling sufficient numbers of eligible patients at traditional 
clinical sites [15]. Meanwhile, as large patient communities 
on the Internet have formed to share experiences and advice 
about living with specific medical conditions [16], these 
online communities have enabled adoption of a direct-to-
patient study design. Direct-to-patient study design allows 
researchers to engage directly with patients through a virtual 
or remote connection rather than through brick and mor-
tar clinical sites [15, 16]. Such obviation of the need for 
recruitment at clinical sites means researchers can access 
large cohorts of eligible patients previously unavailable 
through traditional methods owing to limitations associated 
with geography or a lack of awareness of research opportuni-
ties among eligible members of the patient population [17]. 
Further, it opens the door for all patients to access research 
opportunities, regardless of the settings in which they seek 
their medical care.
Given their close affiliation with patient advocacy, edu-
cation, and/or support organizations, and ability to oper-
ate outside the confines of traditional academic or clinical 
settings, PPRNs are equipped to function as research and 
innovation networks. Patient centeredness is a defining 
feature of each PPRN, and participation is open to all eli-
gible US and, in some cases, non-US patients, whether 
they reside in urban or rural communities, or are seen in 
academic or private practice settings. Studies often focus 
on types of data that help convey the patient experience 
using novel measures of quality of life (e.g., PROs) and 
activity (e.g., wearables, biosensors) [18–22]. As detailed 
in the next section, each PPRN is an enduring infrastruc-
ture with participant data that can be analyzed alone or in 
combination with other data, and with participants who 
can be contacted repeatedly (e.g., by e-mail, social media, 
or in-app messaging) to participate in any number of stud-
ies. Patient-Powered Research Networks thus consist of 
“re-usable” infrastructures to improve research efficiency, 
and can provide data or facilitate data linkage that may 
be used flexibly for clinical, regulatory, administrative, or 
informatics aims [18–22]. Table 1 provides an overview 
of the PPRNs, including conditions of interest, common 
features, and opportunities for researchers and patients to 
propose collaboration.
The ARC convenes these four PPRNs monthly to plan and 
conduct studies and discuss common topics of interest. For 
example, in March 2020, the ARC mobilized rapidly to doc-
ument patients’ attitudes, behaviors, and experiences early 
in the coronavirus disease 2019 (COVID-19) pandemic. The 
ARC’s core team flagged the COVID-19 illness caused by 
infection with severe acute respiratory syndrome coronavi-
rus 2 as particularly worrying to patients with autoimmune 
disease because of their elevated risk of serious infection 
compared with the general population, and compounded by 
their underlying immune dysfunction and reliance on immu-
nomodulatory therapies [23–25]. To better understand how 
the COVID-19 pandemic affected these patients, the ARC 
launched a prospective longitudinal survey to harmonize 
and capture data across the networks, leading to a number 
of timely analyses of autoimmune patients’ real-world atti-
tudes, behaviors, and experience.
The ARC was uniquely prepared to rapidly deploy 
COVID-19 research because of its existing infrastructure 
and that of its constituent PPRNs, including: (1) standing 
meetings with a ready-made team of researchers and patient 
research partners from different institutions and across con-
ditions who convened on a regular basis, (2) past experience 
harmonizing survey items to collect patient data, (3) well-
established data capture portals and mechanisms for cus-
tom survey administration, (4) enduring relationships with 
patients and patient organizations with a history of dem-
onstrated responsiveness to patients’ concerns, (5) online 
patient networks for direct participant recruitment and dis-
semination of findings, (6) connections to health systems for 
relevant EHR data, (7) standing institutional review board 
protocols that allow for the swift assembly of a common pro-
tocol adaptive to PPRN-specific requirements, and (8) ongo-
ing funder contacts to rapidly mobilize support for expenses. 
The project successfully resulted in patient-advised survey 
development, data collection, analysis, and dissemination 
within a few months. Publications resulting from this effort 
reported that patients with autoimmune diseases had a high 
level of concern about COVID-19 and frequent disruptions 
in office visits, routine monitoring, and disease-modifying 
anti-rheumatic drug use, usually without physician approval, 
all of which varied geographically [26–28]. As a result of 
these findings, efforts are now underway to optimize tel-
ehealth in rheumatology, produce patient-facing websites 
(e.g., eRheum.org), and to bring together a multi-stakeholder 
coalition to examine the optimization of vaccine confidence 
among patients with autoimmune disease.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Autoimmune Patient Research Networks
3  Discussion: Common Capacity, 
Characteristics, and Challenges
The ARC’s Autoimmune COVID-19 Project illustrates well 
that the Collaborative and its constituent networks share a 
common capacity and characteristics that enable efficient 
and flexible research design, rapid study implementation, 
and timely dissemination of research results. Patient-Pow-
ered Research Networks seek to leverage and enhance these 
as part of the ARC, while working together to identify and 
address potential challenges that accompany the PPRN 
model. Because PPRNs are by definition situated in, led 
by, or in close partnership with patient advocacy organiza-
tions, there exist opportunities for conducting research that 
engages with and returns value to patients over time. The 
research, education, and advocacy efforts of patient organi-
zations complement one another as these organizations can 
identify gaps in knowledge and then take steps to address 
those gaps via patient-directed information campaigns and 
policy proposals. As patient advocacy organizations are dis-
tinct from pure research institutions, they must hire staff and 
put systems in place to guide the focus, sustainability, rigor, 
and representativeness of their human subject research to be 
optimally effective.
Unlike other longitudinal registries created to answer a 
specific set of pre-determined research questions, PPRNs 
were established to be responsive to the needs and interests 
of their stakeholders. This dynamism creates substantial 
flexibility for PPRNs and the ARC to be responsive to the 
needs of many stakeholders, notably patient partners. More-
over, as patient organizations are often in contact with an 
array of relevant healthcare stakeholders (i.e., patients, care 
partners, researchers, physicians, policy makers, biopharma-
ceutical or equipment manufacturers, regulators, and other 
patient organizations operating within a specific condition), 
PPRNs are able to quickly convene multiple stakeholders, 
an important option for patient-centered outcomes research 
[29]. These relationships can be instrumental in designing, 
funding, implementing, and disseminating studies on timely 
topics, as the COVID-19 project demonstrated.
Although PPRNs no longer rely on PCORnet infrastruc-
ture support from PCORI, this expectation was factored into 
the planning and development of the networks. In the first 
two phases of PCORnet infrastructure development, PCORI 
milestones required PPRNs to develop and submit plans to 
achieve sustainability by the end of the funding period, 
including seeking infrastructure or research support from 
a wide variety of other sources (e.g., National Institutes of 
Health, PCORI, foundations, industry). As PPRNs’ research 
focus is not intended to be tightly controlled by a single 
academic unit or researcher, PPRNs’ research agenda can 
flexibly respond to patients’ concerns. However, this patient-
responsive mandate is not without its challenges. Given the 
high rate of autoimmune disorders among Spanish speakers 
in the USA [30, 31], a limitation of PPRNs is the require-
ment of English proficiency for participation in most stud-
ies. To address this challenge, ArthritisPower is launching 
a completely Spanish version of the network’s smartphone 
application and PRO measures in 2021. Nevertheless, recod-
ing a legacy infrastructure in multiple languages is diffi-
cult and time consuming, something that future researchers 
should heed when building new systems. Patient-friendly 
research topics may also present hurdles. Whereas patients 
often prioritize issues such as nutrition or remedies they 
perceive as being in their immediate control (e.g., changes 
in diet, or use of marijuana to cope with pain), such top-
ics are often accompanied by logistical or financial barriers 
that make them difficult to study. The many impediments to 
conducting trials regarding nutrition [32, 33] or cannabis 
[34–36] are well documented. For example, although many 
patients with inflammatory bowel disease have reported the 
dietary changes that work well for them personally, engaging 
an adequate sample of patients with different phenotypes to 
reach strong conclusions from these patient reports is chal-
lenging [37]. Therefore, PPRNs depend upon their govern-
ance structures, including the prominent role of patient 
governance, to compare and rank various project proposals 
and shape a research agenda over time with an eye to return-
ing value (e.g., information, guidance in treatment decision 
making, new therapies) to patient stakeholders of the PPRN.
Patient leadership in governance [38], along with clearly 
communicated input from other stakeholders, helps establish 
common ground within the PPRNs in the ARC to shape 
and advance projects that align with patient interests. Patient 
governance and patient organizations’ coordination and lead-
ership represent strengths of the PPRN model. But as with 
any individual, research team, or organization, conflicts of 
interest must be made transparent. When there is an oppor-
tunity to conduct a project with financial or staff support 
from an industry partner, these external entities are invited to 
present to the patient governance body, which has the oppor-
tunity to pose questions and make decisions about study 
direction and design. A related imperative for patient organi-
zations leading PPRNs is to hire staff with research exper-
tise. Without a firm commitment from organizational lead-
ership to recruit experienced staff and implement required 
systems, the staff members engaged in research activities 
may lack adequate support and understanding regarding the 
time and logistical or ethical processes required to design 
and conduct human subject research.
Given the commitment to responding to questions that 
arise from the evolving concerns of patients and other stake-
holders, the PPRN infrastructure and data were designed 
to be flexible and durable enough to be used repeatedly for 
various and unanticipated research questions. Perhaps the 
most striking feature of ARC and its constituent PPRNs 
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is its ability to address a wide range of potential research 
questions owing to their adaptability regarding conducting 
research, using existing data and scalable infrastructure, 
or efficiently obtaining new data as needed for a specific 
project. This capacity can be grouped into four categories 
based on the extent to which new data, infrastructure, and 
external collaboration are needed (Table 2). The increase 
in time and effort required to conduct research that accom-
panies each category, and the variability both across and 
within the categories, is based primarily on the extent to 
which: (1) information is readily available for analysis and 
(2) existing staff and patient stakeholders or participants can 
be mobilized to complete research tasks, notably for data 
collection. Although most ARC PPRN projects completed to 
date are clustered in categories I and III, Table 2 shows the 
flexible capacity and potential opportunities to work with an 
individual PPRN, or to engage two or more PPRNs simulta-
neously through the ARC infrastructure.
3.1  Category I
Category I comprises the use of existing data from one or 
multiple PPRNs within the ARC. By leveraging existing 
data assets, these studies are highly efficient. For exam-
ple, ArthritisPower used existing longitudinal data from 
patients with arthritis to evaluate whether instruments 
from the National Institutes of Health Patient-Reported 
Outcomes Measurement Information System (PROMIS) 
[e.g., physical function] could substitute for a commonly 
used Multi-Dimensional Health Assessment Questionnaire. 
Results showed a high degree of cross-measure score predic-
tion [21]. Similarly, IBD Partners performed cross-sectional 
and longitudinal analyses to evaluate associations between 
PROMIS measures and validated disease activity indices 
[39], and iConquerMS explored the relationships between a 
standard assessment of physical function and PROs for lower 
extremity and upper extremity function (Neuro-QoL Adult 
Short Form lower-extremity and upper-extremity domains), 
revealing limitations of the standard assessment (R; H; S; 
L, 2020). The Vasculitis PPRN used its comprehensive 
patient-reported data to demonstrate the utility of patient 
self-reported diagnoses of vasculitis [40]. In a longitudi-
nal study, ArthritisPower observed which PRO measures 
patients with arthritis considered most important to track 
[41]. Findings from these studies provide guidance for future 
projects to minimize participant burden, optimize the mean-
ingfulness of measures to patients, and streamline research 
using decentralized (virtual) trials.
Existing data have also been used to examine medica-
tion safety and effectiveness. IBD Partners evaluated the 
real-world effectiveness of vedolizumab, focusing on 
patient-reported disease activity, use of glucocorticoids, 
and PROMIS measures [20]. Working collectively across 
the Collaborative, autoimmune PPRNs (ArthritisPower, IBD 
Partners, and the Vasculitis PPRN) used existing clinical 
data and health-related quality-of-life assessments collected 
Table 2  Capacity of PPRNs to conduct patient-centered research individually or collectively within the Autoimmune Research Collaborative
PPRN Patient-Powered Research Network
a External partners include, but are not limited to, PCORnet Health Plan Research Networks and Clinical Research Networks







Secondary use of existing PPRN data Linkage to external data sources for additional secondary use of existing 
PPRN data
Direct-to-patient recruitment for external studies
Patient representatives to advise on topics of interest Linkage with external health plans or health systems to conduct PPRN-led 







Prospective survey data collection Collaboration with external partner(s) for prospective survey data collection, 
patient participants for qualitative studies, or direct-to-patient translational 
studies, and precision medicine
Patient participants for qualitative studies
Direct-to-patient pragmatic trials, translational stud-
ies, and precision medicine
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longitudinally to compare how well patients respond to 
immunomodulating treatment and how often patients receiv-
ing these treatments experience serious adverse events [42]. 
Results from such real-world studies are important topics 
for broad dissemination to guide autoimmune patients and 
their doctors as they select from an expanding assortment of 
disease-modifying antirheumatic drugs.
Patient-Powered Research Networks maintain a roster 
of thousands of “research-ready” participants who have 
agreed to be contacted for future research opportunities. 
Thus, PPRNs can rapidly screen individuals based on demo-
graphic or clinical characteristics for preparatory to research 
efforts, and selectively provide referrals for external studies 
for which they may qualify. Such direct-to-patient recruit-
ment can bypass the need to work through and contract with 
study centers, enabling efficient start-up. Several studies 
have demonstrated the quick and flexible nature of research 
recruitment via PPRNs. IBD Partners identified pregnant 
patients treated with certain medications and referred them 
to the Mother to Baby Registry [43]. ArthritisPower targeted 
patient recruitment based on condition, geography, and other 
eligibility criteria to assist with National Institutes of Health 
clinical trials studying a new vaccine among older patients 
with inflammatory arthritis [44], and the impact of tumor 
necrosis factor inhibitors on the risk of cardiovascular dis-
ease [45].
Because PPRN participants are often recruited via digi-
tal or social marketing using an “opt in” direct-to-patient 
approach, the resulting group of patients may constitute 
convenience samples of patients living with these condi-
tions rather than truly representative samples of a broader, 
more generalizable group of patients. Patients seeking health 
information or research participation online may be more 
engaged than many patients recruited from clinical settings, 
and PPRN participant groups also tend to skew more female, 
white, middle-aged, and college educated [46, 47]. To some 
degree, this may diminish the generalizability of study find-
ings to a more general population of affected patients. How-
ever, for most studies, including prospective studies that 
evaluate the effect of an exposure (medication, diet, health 
behavior) on an outcome (PRO, disease-specific measure), 
the convenience sampling does not pose a substantial threat 
to internal validity. Recruitment in most types of medical 
research involves studying not fully representative popula-
tions, especially including randomized clinical trials based 
at major urban medical centers with strict eligibility crite-
ria. Each research system offers advantages and limitations, 
but by broadening the overall population of patients under 
study and facilitating rapid large-scale participation, studies 
through ARC bring a new dimension to medical research.
Patient-Powered Research Networks have explored poten-
tial selection bias, sometimes referred to as the “volunteer 
effect” [48], in their respective datasets by comparing the 
demographic characteristics of their direct-to-patient mem-
bership with that of clinical PCORnet data overall. For 
example, based on a 2016 PCORnet query yielding demo-
graphic data on ~88,000 people with MS across PCORnet 
Clinical Research Networks, iConquerMS found that their 
network participants had roughly the same sex distribution, 
though age distribution in their PPRN member group skewed 
slightly older, and racial/ethnic subpopulations were under-
represented, compared with the multiple sclerosis popula-
tion within PCORnet Clinical Research Networks. Overall, 
potential selection bias in PPRN samples can be mitigated 
by weighting opt-in responses during the analysis to cre-
ate synthetic samples representative of the population being 
studied [49] or by linking or partnering with other datasets 
or organizations for targeted outreach to groups that are not 
well represented in the network (see Category II).
To examine the strengths and limitations of direct-to-
patient trial recruitment by PPRNs, the Vasculitis PPRN 
compared trial recruitment of patients with a rare disease 
(granulomatosis with polyangiitis) using a direct-to-patient, 
web-based recruitment approach of social marketing strate-
gies with a standard multi-site Center of Excellence recruit-
ment approach. The direct-to-patient approach included a 
website with an interactive informed consent form to enroll 
in the study; the standard approach meant participants were 
recruited by investigators at clinical sites who adminis-
tered the consent process. The study found that although 
the web-based method was less successful than the standard 
approach, it was good at confirming eligibility and was as 
acceptable to providers and as understandable to patients as 
the standard approach [15].
Patient participants are also available to be engaged as 
advisors on topics of interest. iConquerMS accessed its net-
work participants to create a Patient-Focused Drug Devel-
opment Council that provided continuing input on clinical 
trial design, outcome measures, including PROs, proposed 
label statements, and trial participant training materials 
prior to launch of phase III clinical trials for evobrutinib 
[19]. Patient-Powered Research Networks offer a curated 
approach to contacting or convening patient representatives 
by matching suitable patients to the needs of a particular 
research development project, advisory panel, or other group 
where patient stakeholder input is needed.
Understanding methods of patient engagement, for eve-
rything from study recruitment, to measuring what matters 
to patients, to patient research leadership and governance, 
is a growing area of interest among academic medical 
centers, industry, and other research entities [50, 51]. The 
PPRNs in ARC, individually and together, have dynamic 
living laboratories of patient populations through which 
different engagement strategies can be assessed to deter-
mine their relative effectiveness. The variability within and 
across patient populations under study in the ARC offers 
 W. B. Nowell et al.
opportunities to study multiple potential engagement strate-
gies, allowing refinement of approaches and/or use of dif-
ferent approaches for different types of research. Cultivating 
deep patient engagement with PPRN members is both an 
imperative and a persistent challenge for our networks, thus 
a potential vulnerability of the direct-to-patient approach 
to research. Because PPRN participants elect to participate 
primarily virtually, as opposed to attending scheduled in-
person physician visits at regular intervals where clinical 
assessments and data collection can be done, PPRNs must 
maintain patients’ interest over time to motivate members to 
check their e-mail, log in to web portals or apps, and provide 
information about themselves. Opt-in samples from e-mail 
surveys also create a reporting challenge for documenta-
tion of participant response. In short, use of a traditional 
“response rate” should be avoided when reporting response 
metrics for the web-based or online surveys often used by 
PPRNs. It is more appropriate to instead calculate metrics 
such as the view rate (e.g., how many people opened an 
e-mail invitation and saw the survey), participation rate, and 
completion rate, as these use numerators and denominators 
that are more accurate and insightful for reporting the par-
ticipation of eligible individuals [52].
Considering as the denominator the entire population 
of e-mails sent out to potential participants in a PPRN 
community artificially deflates the response rate. A more 
appropriate denominator would be the open rate (number 
of participants who opened the e-mail) as an indicator of 
the population of individuals who were aware of the study 
and therefore able to make a decision about their participa-
tion. The ARC recently defined shared metrics for tracking 
engagement over time beyond simple numbers of consented 
participant membership. By developing standard definitions 
for PPRN member activity, such as providing longitudinal 
data within certain time periods, and participant contribu-
tions or interactions beyond data sharing, will help advance 
common ARC approaches to engaging participants and 
returning value to patients for PPRN participation.
3.2  Category II
Because of their reliance on a direct-to-patient structure that 
favors patient-reported data, PPRNs must collect or be able 
to readily obtain clinical data such as physician-reported 
assessments or specific diagnostic tests. This often means 
collaborating and linking data with health systems and other 
clinical registries outside of PPRNs’ usual partnerships, 
requiring that each PPRN have an informed consent form 
in place that specifies such permissions. As the ARC and 
its PPRNs have put in place such consent permissions, and 
maintain the capacity to link to clinical or administrative 
records maintained by Clinical Research Networks, Health 
Plan Research Networks, or other non-PCORnet entities, 
they are able to expand their existing data and research infra-
structure for secondary data analysis or other observational 
and interventional studies by working with external partners 
such as clinical registries, health systems, or health plans 
(claims/administrative). These collaborations enable rich 
linked datasets that can enhance a study’s capacity, even 
making patient-reported data available at the clinical point of 
care. Patient-Powered Research Networks can also serve as a 
venue for efficient, long-term, direct-to-patient follow-up for 
observational studies that may be ending [53, 54].
Beyond the informed consent process, other fundamen-
tal steps needed for PPRNs to perform data expansion 
include privacy preserving linkages to connect patient data 
from two or more entities, and computable phenotypes to 
identify patients with conditions of interest based solely on 
EHR or claims data. A computable phenotype refers to an 
algorithm that can be shared and reproduced that defines a 
condition, disease, clinical event, or other complex patient 
characteristic as precisely as possible using only information 
processed digitally (i.e., EHR data) [55]. To date, projects 
in Category II have mainly focused on the development and 
validation of computable phenotypes in large administrative 
databases and the examination of viable methods for data 
linkage in a manner that preserves patient privacy. For exam-
ple, ArthritisPower, iConquerMS, and the Vasculitis PPRN 
collaborated with the HealthCore Health Plan Research Net-
work to test computable phenotypes and engagement strat-
egies linking PPRN data with 14 health plans [53], facili-
tating access to EHR data (physician encounter, laboratory 
results, disease activity). The Vasculitis PPRN developed 
and validated computable phenotypes for several types of 
vasculitis in three large administrative databases [56]. IBD 
Partners collaborated with an industry partner on develop-
ing and testing methods for the recruitment and linkage of 
participants from existing cohort studies to the PPRN [57]. 
ArthritisPower has additionally linked patient-reported data 
to Medicare claims data [42], and to an EHR vendor system 
for community medical practices to enable real-time studies 
linking to PRO data, bringing patient data to the point of 
care. These efforts underscore PPRNs’ innovative methods 
and flexible infrastructure to facilitate access to, and aug-
ment patient-generated data.
3.3  Category III
Existing research infrastructure (regulatory, informatics) 
allows for efficient start-up, recruitment, and prospective 
data collection. As the Autoimmune COVID-19 Project 
demonstrates, PPRNs can reach large numbers of patients 
quickly to collect new data and data types, for cross-sec-
tional or longitudinal studies. Patient-Powered Research 
Network patient members can be screened with existing data 
to select for certain characteristics (age, disease type, clinical 
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characteristics) and new survey information can be com-
bined with existing registry data for more efficient studies. 
There are many examples of such work among the individual 
PPRNs in the ARC. The Vasculitis PPRN rapidly conducted 
surveys using new data forms to study work disability [58], 
patients’ pathways to arriving at a diagnosis [59], and patient 
preferences for glucocorticoids and health-related quality 
of life among patients with vasculitis. IBD Partners imple-
mented a new survey module to evaluate patient activation 
and learned that patients with higher levels of patient activa-
tion are more likely to be in remission [60], and iConquerMS 
has implemented targeted surveys for evaluation of: patient 
access to insurance; effectiveness of adult day care facilities; 
and attitudes to disease-modifying therapies and willingness 
to pay for them [18, 61, 62]. Each of these studies shows that 
new data elements can be added within the PPRN infrastruc-
ture at any time, and that prospective studies can be initiated 
quickly to address any number of research questions about 
autoimmune patient attitudes, behaviors, experiences, and 
preferences.
Patient participants are also available to be recruited 
directly by PPRNs or ARC for qualitative studies. For exam-
ple, IBD Partners conducted a qualitative study to evaluate 
patient perceptions of biobanking and situations in which 
patients would be willing to donate samples. A series of 
one-on-one interviews informed the development of a full 
survey that was successfully distributed to the larger PPRN 
population [63].
Direct-to-patient pragmatic trials can also be embedded in 
one or more of the PPRN platforms. If study focus and eligi-
bility criteria are broad and clinician involvement minimal 
or not required, this can be an effective method to complete 
a trial, often without the need for clinical site visits. IBD 
Partners, for example, conducted a randomized controlled 
trial comparing two diets in patients with Crohn’s disease 
in remission, finding that the amount of red and processed 
meat consumed was not associated with flares or relapses 
[64]. Patient-Powered Research Networks can further add a 
new infrastructure, building on their existing patient engage-
ment platforms to conduct studies. ArthritisPower built a 
custom mobile app workflow for prospective PRO data col-
lection among patients with rheumatoid arthritis to charac-
terize the extent to which activity measures collected from 
a smartwatch agree with PRO measures [22]. This means 
that customized protocols or workflows to guide participants 
through study tasks, including use of novel digital health 
technologies such as wearables, can be created or incorpo-
rated by PPRNs for the collection of new data types.
3.4  Category IV
The ARC or its constituent PPRNs can also collaborate with 
external partners to collect prospective survey data, recruit 
patients for qualitative studies, or gather new clinical or 
translational data. For example, biosamples (salivary DNA 
collection, stool collection for microbiome analysis) may 
be collected to facilitate translational or precision medicine 
studies and there are a number of possible options for doing 
so: (1) collection by diagnostic laboratory services company 
through which participants are shipped a blood collection 
and pre-paid shipping kit with masked, de-identified, and 
bar-code-labeled tubes to bring to a participating laboratory 
for blood draw and processing; (2) collection by a health-
care provider that is either participant or (3) provider driven 
where a healthcare provider’s office performs the blood 
draw and processing using a kit brought in by the participant 
(option 2) or available to the provider (option 3); (4) speci-
men collection by a home health nurse; or (5) collection via 
a home saliva kit, a DNA-only option, where participants 
receive a pre-paid shipping kit, spit into a tube, and mail 
it back. IBD Partners conducted a pilot study to compare 
the feasibility of various biospecimen collection procedures 
and found that home saliva kits yielded the highest return 
rate [65]. In an ongoing follow-up study, IBD Partners iden-
tified patients with selected rare phenotypes to contribute 
saliva for DNA extraction and a genome-wide association 
scan. iConquerMS has also piloted saliva collection from a 
small subset of its membership with IRB approval, kits, and 
consents. These category IV pilots demonstrate the open 
and flexible nature of PPRNs to expand their available data 
and to engage with patients in new ways for future studies. 
As the study examples presented here demonstrate, the sub-
stantial flexibility of the PPRNs, individually or together, 
support a range of direct-to-patient research activities from 
a quick and efficient secondary analysis of single network 
data to more sophisticated collaborative efforts with external 
partners where new data must be gathered or combined.
4  Conclusions
Patient-Powered Research Networks have the capacity to 
conduct a range of real-world, direct-to-patient research and 
engagement activities comprising virtual study recruitment 
and data collection methods, innovative informatics such as 
novel methods for data linkage, and systems that promote 
dissemination of relevant information to healthcare stake-
holders via digital health. While the role of patient-generated 
data to provide data for real-world evidence is still evolving, 
relevant direct-to-patient innovation and patient-centered 
outcomes research is already underway within the ARC and 
its four constituent PPRNs for arthritis, inflammatory bowel 
disease, multiple sclerosis, and vasculitis.
Research conducted by, or in collaboration with, patient 
organizations can return value to patients in a variety of ways 
for participation in the PPRN or in specific studies. Ideally, 
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when PPRNs are aligned with principles of patient-centered 
outcomes research, they engage with patients repeatedly 
over time to identify patient concerns and turn them into 
patient-centric research questions and study designs, recruit 
patients to participate in studies, enlist patients in registry 
governance and in the analysis and interpretation of findings, 
provide educational content to patient communities using 
the most up-to-date evidence, and advocate for health policy 
to patients’ benefit. From its origins in PCORnet, the chal-
lenges confronting PPRNs were spelled out in the expecta-
tions of such a shared infrastructure:
“... collecting relevant clinical data, including informa-
tion from patient self-reports and from their network’s 
EHRs; harmonizing data so that they can be useful to 
... [other partners]; increasing the numbers of patients 
with a single condition who are registered and willing 
to share data, participate in research (including inter-
ventional studies), prioritize research questions, and 
disseminate results; establishing patients’ trust with 
respect to the privacy and security of their personal 
information; streamlining the consent and IRB pro-
cesses while protecting patients’ rights; and meaning-
fully engaging patients in the networks’ governance” 
[12].
The four PPRNs that make up the ARC have met these 
expectations and continue to grow and improve their infra-
structure together.
The ARC provides a single point of entry for research into 
multiple autoimmune diseases that share important simi-
larities, along with a wide net of collaborators and experts, 
including physician researchers and patients, to draw from. 
The focus of collaboration is to share resources and work, 
and to learn from each other to constantly improve indi-
vidual PPRNs. The COVID-19 project and shared metrics 
for tracking engagement over time represent recent examples 
of working together in the ARC to develop shared definitions 
and solutions that will improve such an infrastructure. As 
COVID-19 vaccination is rolled out, the ARC is initiating 
projects to better understand the reactions of patients with 
autoimmune diseases to the vaccine and to combat misin-
formation while increasing vaccine confidence and trust in 
our patient communities.
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